Multi messenger Imaging of Cancer

Informations projet

MIC

N° de convention de subvention: 101032769

DOI

10.3030/101032769

Projet clôturé

Date de signature de la CE 30 Avril 2021

Date de début 1 Janvier 2022

Date de fin 31 Decembre 2023

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total

€ 175 572,48

Contribution de l’UE

€ 175 572,48

Coordonné par

TECHNISCHE UNIVERSITEIT DELFT
Netherlands

Periodic Reporting for period 1 - MIC (Multi messenger Imaging of Cancer)

Période du rapport: 2022-01-01 au 2023-12-31

Résumé du contexte et des objectifs généraux du projet

Cancer remains the second leading cause of death worldwide according to the World Health Organization. It is a complex affliction which involves many biological processes across scales. Several imaging techniques are at a doctor's disposal in clinical practice to fight cancer. Echography, which relies on the transmission and reception of ultrasound waves, is increasingly used in to monitor cancer patients and guide therapy. Unfortunately, ultrasound is not yet capable of detecting early signs of cancer at the microscale. The aim of this research project is to develop an echography approach that enables imaging of early metabolic and vascular signs of cancer in a preclinical studies and if successful, in a pilot study in head and neck cancer patients in collaboration with Erasmus Medical Centre in Rotterdam, the Netherlands. This interdisciplinary research builds on three recent breakthroughs in the field of ultrasound: the development of high-speed 3D ultrasound imaging, the development of super-resolved ultrasound imaging of blood vessels, and the development of ultrasound biosensors capable of probing molecular environments in tissues.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

In the course of this project, we successfully developed a 3D ultrasound imaging method that works with a new class of large field of view ultrasound probes called row-column addressed arrays. With these new ultrasound probes, we showed that we can detect with a high sensitivity two important type of ultrasound contrast agents: gas-filled microbubbles used to visualize blood vessels, and protein-based nanostructures used to label cells with ultrasound contrast.
Using this novel capability, we showed that ultrasound imaging gene expression in cancer cells is now possible, and that cerebral blood vessels can be now detected in arbitrary planes of interest.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Our project has improved upon the state of the art of three different fields.
First, we have successfully developed a high-speed ultrasound imaging technique that can detect the nonlinear scattering of ultrasound contrast agents in deep tissue.
Second, using this technique, we have achieved volumetric ultrasound imaging of a new kind of ultrasound contrast agent for the first time.
Third, we successfully achieved ultrasound imaging of the cerebral vasculature in selective planes of interest in rodents.
Just as the field of optical fluorescence microscopy enabled breakthrough studies of cellular function in translucent organisms, we anticipate that the combination of 3D ultrasound imaging with utltrasound contrast agents, acoustic reporter genes and acoustic biosensors will unlock ultrasound imaging of cellular functions deep in mammalian tissues.
The research led to the filing of an invention, and the potential for commercialization of our imaging technique will be explored. Our research results have been communicated at multiple scientific events and schools to train future generations of scientists in the field of molecular ultrasound imaging.

3D ultrasound image of protein nanostructures